Skip to content

Dexamethasone Palmitate for PONV After Craniotomy

Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06988124
Enrollment
500
Registered
2025-05-23
Start date
2025-06-25
Completion date
2027-06-01
Last updated
2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Brief summary

Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients undergoing craniotomy still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after craniotomy.

Interventions

DRUGDexamethasone

Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.

Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18 to 65 years; * Providing written informed consent; * Perform elective craniotomy undergoing general anesthesia.

Exclusion criteria

* Known to be allergic to dexamethasone; * Any systemic glucocorticoids within 3 months before trial entry; * History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al); * Cognitive impairment or severe mental illness; * Uncontrolled diabetes or infectious diseases; * Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
The incidence of PONVWithin the first 24 hours postoperativelyPONV will be defined as any nausea, emetic episodes (vomiting or retching), or both. Nausea is defined as an unpleasant sensation with an urge to vomit. Vomiting is defined as the physical event of forcefully expelling gastric contents through the mouth. Retching refers to the forced movement of gastrointestinal contents without actual expulsion of vomitus.

Secondary

MeasureTime frameDescription
Incidence of postoperative nausea (PON) and postoperative vomiting (POV)At 6 hours, 24 hours, 48 hours, and 72 hours postoperativelyIncidence of postoperative nausea (PON) and postoperative vomiting (POV)
The number of vomiting or retching episodesWithin 6 hours, 24 hours, 48 hours, and 72 hours postoperativelyThe number of vomiting or retching episodes
The severity of PONVAt 6 hours, 24 hours, 48 hours, and 72 hours postoperativelyThe severity of PONV will be measured using the simplified PONV impact scoring system. The simplified PONV impact scoring system evaluates the nausea impact subscale and vomiting frequency score. Nausea impact subscale scoring will be rated by visual analogue scales (VAS) (0 = no impact to 10 = maximum impact). The VAS scores will be converted to 0-3 points via predefined thresholds. The Vomiting Frequency Score is categorized as follows: 0 for no episodes, 1 for 1-2 episodes, 2 for 3-5 episodes, and 3 for 6 or more episodes. The total score is calculated as the sum of the VAS-derived nausea impact score and the vomiting frequency score
Participant satisfaction with PONV managementAt 6 hours, 24 hours, 48 hours, and 72 hours postoperativelyParticipant satisfaction will be also rated by visual analogue scales (VAS) (0 = very dissatisfied to 10 = most satisfied imaginable).
The Incidence of PONVAt 6 hours, 48 hours, and 72 hours postoperativelyPONV will be defined as any nausea, emetic episodes (vomiting or retching), or both. Nausea is defined as an unpleasant sensation with an urge to vomit. Vomiting is defined as the physical event of forcefully expelling gastric contents through the mouth. Retching refers to the forced movement of gastrointestinal contents without actual expulsion of vomitus.
The quality of postoperative recovery (QoR)At 24 and 48 hours postoperatively, discharge, and 1 month postoperativelyThe quality of postoperative recovery (QoR) will be assessed by the 15-item quality of recovery scoring system \[QoR-15\]
The VAS scaleAt 6 hours, 24 hours, 48 hours, and 72 hours postoperativelyThe VAS scale (0 = no pain to 10 = maximum pain)
Postoperative length of stay (LOS)Within 1 month postoperativelyPostoperative length of stay (LOS)
Safety outcomesWithin 1 month postoperativelySuch as hypotension, bradycardia, hypertension, tachycardia, et al.
The use of rescue antiemetic drugsDuring the 0-24 hours, 24-48 hours, and 48-72 hours postoperativelyThe use of rescue antiemetic drugs

Countries

China

Contacts

Primary ContactFang Luo
13611326978@163.com59976661

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026